TREATMENT OF FABRY DISEASE IN ERT-NAIVE AND ERT-EXPERIENCED PATIENTS

摘要

Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-nave Fabry patients. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for improving left ventricular mass and/or improving podocyte globotriaosylceramide.